Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 153.88B, Pfizer(PFE) trades at $27.03. The stock has a price-to-earnings ratio of 19.60 and currently yields dividends of 6.5%.
During the trading session on 2026-02-23, Pfizer(PFE) shares reached a daily high of $27.15 and a low of $26.50. At a current price of $27.03, the stock is +2.0% higher than the low and still -0.4% under the high.
Trading volume for Pfizer(PFE) stock has reached 34.17M, versus its average volume of 42.32M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
PFE News
Advertisement Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus as investors reassess the stock after a period of mixed returns, wit...
There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head. Does your portfolio need so...
Pfizer (NYSE: PFE) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and an...
Analyst ratings
61%
of 28 ratingsMore PFE News
Key Points The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind com...
Key Points Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through...
Barclays analyst Emily Field initiated coverage of Pfizer (PFE) with an Underweight rating and $25 price target Pfizer is “managing through a difficult period,”...
Pfizer (NYSE:PFE) reported positive pivotal Phase 3 trial results for BRAFTOVI in combination with cetuximab and FOLFIRI in BRAF V600E-mutant metastatic colorec...
Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weig...
Mixed options sentiment in Pfizer (PFE), with shares down 6c near $27.32. Options volume relatively light with 33k contracts traded and calls leading puts for a...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a new real-world study in Taiwan to track how its multiple...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.